Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fexofenadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.89 |
| ▸ | LMNA | P02545 | 3/20 | 0.89 |
| ▸ | DRD3 | P35462 | 3/20 | 0.89 |
| ▸ | HTR2A | P28223 | 2/20 | 0.89 |
| ▸ | HTR2B | P41595 | 2/20 | 0.89 |
| ▸ | BLM | P54132 | 2/20 | 0.89 |
| ▸ | CNR1 | P21554 | 1/20 | 0.89 |
| ▸ | APEX1 | P27695 | 1/20 | 0.89 |
| ▸ | PDE4A | P27815 | 1/20 | 0.89 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.89 |
| ▸ | DRD2 | P14416 | 2/20 | 0.87 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.87 |
| ▸ | CYP2J2 | P51589 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | NPC1 | O15118 | 1/20 | 0.74 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.74 |
| ▸ | GMNN | O75496 | 1/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fexofenadine SCHEMBL7104316 | 0.94 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL4900 | 0.94 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1561082 | 0.94 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1972366 | 0.94 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL3178320 | 0.94 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL4901 | 0.94 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1395674 | 0.93 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL16651410 | 0.93 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL9943444 | 0.93 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL20531399 | 0.93 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017161387-A1 | COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES | REID CHRISTOPHER BRIAN (US) | 2017-09-21 | — | — | WO | claimed |
| US-20140271923-A1 | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions | REID CHRISTOPHER BRIAN (US) | 2014-09-18 | — | — | US | claimed |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12384792-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | TWELVE THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12377113-B2 | Glycan therapeutic compositions and related methods thereof | DSM NUTRITIONAL PRODUCTS, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4585268-A2 | SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME | Twelve Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250171453-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-3350183-B1 | SOLID FORMS OF ISOQUINOLINONE DERIVATIVES, PROCESS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2025-04-02 | — | — | EP | disclosed |
| US-20250049716-A1 | Membrane Encapsulated Nanoparticles and Method of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-02-13 | — | — | US | disclosed |
| US-20250049715-A1 | Membrane Encapsulated Nanoparticles and Method of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-02-13 | — | — | US | disclosed |
| US-20250017860-A1 | Membrane Encapsulated Nanoparticles and Method of Use | UNIV CALIFORNIA (US) | 2025-01-16 | — | — | US | disclosed |
| US-20020102305-A1 | Osmotic device containing pseudoephedrine and an H1antagonist | Osmotica Kereskedelmi és Szolgáltató KFT (HU) | 2002-08-01 | — | — | US | disclosed |
| WO-2001078782-A1 | SINGLE-DOSE ANTIHISTAMINE/DECONGESTANT FORMULATIONS FOR TREATING RHINITIS | J-MED PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| US-6270796-B1 | PREFILLED, UNIFYING DISPENSING CONTAINER OF AT LEAST TWO DIFFERENT MEDICATION DOSAGE UNITS; INDICIA FOR DISTINGUISHING THE DOSAGE UNITS, AND COORDINATING INSTRUCTIONS. | J-MED PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| US-20010011102-A1 | Single-dose antihistamine/decongestant formulations for treating rhinitis | J-MED PHARMACEUTICALS, INC. | 2001-08-02 | — | — | US | disclosed |
| WO-2001051038-A1 | OSMOTIC DEVICE CONTAINING PSEUDOEPHEDRINE AND AN H1 ANTAGONIST | OSMOTICA CORP. (VG) | 2001-07-19 | — | — | WO | disclosed |
| EP-1032392-A4 | ANTIHISTAMINE/DECONGESTANT REGIMENS FOR TREATING RHINITIS | J MED PHARMACEUTICALS INC (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1032392-A1 | ANTIHISTAMINE/DECONGESTANT REGIMENS FOR TREATING RHINITIS | J-Med Pharmaceuticals, Inc. (US) | 2000-09-06 | — | — | EP | disclosed |
| US-6051585-A | Single-dose antihistamine/decongestant formulations for treating rhinitis | J-MED PHARMACEUTICALS, INC. | 2000-04-18 | — | — | US | disclosed |
| WO-1999021556-A1 | ANTIHISTAMINE/DECONGESTANT REGIMENS FOR TREATING RHINITIS | J-MED PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PRKCB, PRKCD, PRKCA | HRH1 1550/4885KCNH2 2365/4885LMNA 1489/4885 |
| US-12384792-B2 | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same | PIK3CA, PIK3C2A, PIK3CD | HRH1 2080/4885KCNH2 2946/4885LMNA 888/4885 |
| US-20250171453-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | HRH1 1644/4885KCNH2 4229/4885LMNA 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.